{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:15Z","timestamp":1790108775445,"version":"4.0.1"},"reference-count":68,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","award":["109861-65-RKNT"],"award-info":[{"award-number":["109861-65-RKNT"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Viral entry into host cells is a critical step in the viral life cycle. HIV-1 entry is mediated by the sole surface envelope glycoprotein Env and is initiated by the interaction between Env and the host receptor CD4. This interaction, referred to as the attachment step, has long been considered an attractive target for inhibitor discovery and development. Fostemsavir, recently approved by the FDA, represents the first-in-class drug in the attachment inhibitor class. This review focuses on the discovery of temsavir (the active compound of fostemsavir) and analogs, mechanistic studies that elucidated the mode of action, and structural studies that revealed atomic details of the interaction between HIV-1 Env and attachment inhibitors. Challenges associated with emerging resistance mutations to the attachment inhibitors and the development of next-generation attachment inhibitors are also highlighted.<\/jats:p>","DOI":"10.3390\/v13050843","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T22:36:24Z","timestamp":1620426984000},"page":"843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-6417","authenticated-orcid":false,"given":"Yen-Ting","family":"Lai","sequence":"first","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4081\/idr.2013.s1.e6","article-title":"Pathogenesis of HIV infection","volume":"5","author":"Naif","year":"2013","journal-title":"Infect. Dis. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/HIV.S79956","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Wang","year":"2015","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV Protease Inhibitors: Raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1570162X15666171120110145","article-title":"Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics","volume":"15","author":"Holec","year":"2018","journal-title":"Curr. HIV Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989\u20132009)","volume":"85","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Messiaen, P., Wensing, A.M.J., Fun, A., Nijhuis, M., Brusselaers, N., and Vandekerckhove, L. (2013). Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052562"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.2147\/DDDT.S90580","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"9","author":"Kanmogne","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/13543776.2014.987752","article-title":"Peptide fusion inhibitors targeting the HIV-1 gp41: A patent review (2009\u20132014)","volume":"25","author":"Zhang","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","article-title":"Life expectancy of HIV-positive people after starting combination antiretroviral therapy: A meta-analysis","volume":"18","author":"Teeraananchai","year":"2017","journal-title":"HIV Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"l4179","DOI":"10.1136\/bmj.l4179","article-title":"Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: Systematic review and meta-analysis of randomised controlled trials","volume":"366","author":"Feng","year":"2019","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jmb.2011.04.042","article-title":"HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation","volume":"410","author":"Checkley","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25269","DOI":"10.1073\/pnas.1910008116","article-title":"Single-molecule imaging of HIV-1 envelope glycoprotein dynamics and Gag lattice association exposes determinants responsible for virus incorporation","volume":"116","author":"Pezeshkian","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imr.12507","article-title":"The HIV-1 envelope glycoprotein structure: Nailing down a moving target","volume":"275","author":"Ward","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41467-020-16165-0","article-title":"Structural basis of transmembrane coupling of the HIV-1 envelope glycoprotein","volume":"11","author":"Piai","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/bmb\/58.1.43","article-title":"HIV-1 receptors and cell tropism","volume":"58","author":"Clapham","year":"2001","journal-title":"Br. Med. Bull."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41594-019-0344-5","article-title":"Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody","volume":"26","author":"Yang","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nsmb.3382","article-title":"Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer","volume":"24","author":"Liu","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular Mechanism of HIV-1 Entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41586-018-0804-9","article-title":"Structural basis of coreceptor recognition by HIV-1 envelope spike","volume":"565","author":"Shaik","year":"2019","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1462-5822.2012.01812.x","article-title":"The molecular basis of HIV entry","volume":"14","author":"Klasse","year":"2012","journal-title":"Cell. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2174\/1568026615666150901114527","article-title":"Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41","volume":"16","author":"Lu","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1517\/14656566.2010.522178","article-title":"Enfuvirtide: From basic investigations to current clinical use","volume":"11","author":"Joly","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11013","DOI":"10.1073\/pnas.1832214100","article-title":"A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding","volume":"100","author":"Lin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/jm034082o","article-title":"Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","article-title":"Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10528","DOI":"10.1128\/JVI.77.19.10528-10536.2003","article-title":"Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions","volume":"77","author":"Guo","year":"2003","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1097\/00002030-200411190-00015","article-title":"Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G","volume":"18","author":"Moore","year":"2004","journal-title":"AIDS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/jssc.200600499","article-title":"Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography\/tandem mass spectrometry","volume":"30","author":"Xue","year":"2007","journal-title":"J. Sep. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/jm201218m","article-title":"Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)","volume":"55","author":"Kadow","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/AAC.00759-10","article-title":"Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects","volume":"55","author":"Hanna","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01173-10","article-title":"In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043","volume":"55","author":"Zhou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.bmcl.2003.08.029","article-title":"Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: Synthesis and biological properties","volume":"13","author":"Ueda","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ejmech.2014.09.012","article-title":"Discovery of small molecular inhibitors targeting HIV-1 gp120\u2013CD4 interaction drived from BMS-378806","volume":"86","author":"Liu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bmcl.2015.11.009","article-title":"Inhibitors of HIV-1 attachment: The discovery and structure\u2013activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore","volume":"26","author":"Swidorski","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1128\/AAC.00639-12","article-title":"HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug","volume":"56","author":"Schader","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00426-12","article-title":"In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068","volume":"56","author":"Gong","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0000000000001602","article-title":"Viral Drug Resistance through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir","volume":"77","author":"Lataillade","year":"2018","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00513-13","article-title":"Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors","volume":"57","author":"Li","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.0307953101","article-title":"Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins","volume":"101","author":"Si","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbapap.2005.12.017","article-title":"Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation","volume":"1764","author":"Kong","year":"2006","journal-title":"Biochim. Biophys. Acta (BBA) Proteins Proteom."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/prot.24726","article-title":"Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action","volume":"83","author":"Langley","year":"2015","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41467-018-07851-1","article-title":"Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry","volume":"10","author":"Lai","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41467-017-01119-w","article-title":"The beta20-beta21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions","volume":"8","author":"Herschhorn","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.1112391109","article-title":"Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops","volume":"109","author":"Kwon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kwon, Y.D., LaLonde, J.M., Yang, Y., Elban, M.A., Sugawara, A., Courter, J.R., Jones, D.M., Smith, A.B., Debnath, A.K., and Kwong, P.D. (2014). Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085940"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/ml300407y","article-title":"Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization","volume":"4","author":"LaLonde","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ofid\/ofy242","article-title":"Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART","volume":"5","author":"Riddler","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-981-13-0484-2_3","article-title":"HIV Broadly Neutralizing Antibodies: VRC01 and Beyond","volume":"1075","author":"Wu","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Julg, B., Pegu, A., Abbink, P., Liu, J., Brinkman, A., Molloy, K., Mojta, S., Chandrashekar, A., Callow, K., and Wang, K. (2017). Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J. Virol., 91.","DOI":"10.1128\/JVI.00498-17"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cohen, Y.Z., Butler, A.L., Millard, K., Witmer-Pack, M., Levin, R., Unson-O\u2019Brien, C., Patel, R., Shimeliovich, I., Lorenzi, J.C.C., and Horowitz, J. (2019). Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219142"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fellinger, C.H., Gardner, M.R., Weber, J.A., Alfant, B., Zhou, A.S., and Farzan, M. (2019). eCD4-Ig Limits HIV-1 Escape More Effectively Than CD4-Ig or a Broadly Neutralizing Antibody. J. Virol., 93.","DOI":"10.1128\/JVI.00443-19"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eaau5409","DOI":"10.1126\/scitranslmed.aau5409","article-title":"AAV-delivered ecd4-Ig protects rhesus macaques from high-dose sivmac239 challenges","volume":"11","author":"Gardner","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000367","article-title":"Engineering antibody-like inhibitors to prevent and treat HIV-1 infection","volume":"12","author":"Gardner","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18719","DOI":"10.1073\/pnas.2010320117","article-title":"Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells","volume":"117","author":"Hoffmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:38Z","timestamp":1760162258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050843"],"URL":"https:\/\/doi.org\/10.3390\/v13050843","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}